The present disclosure relates to using spectrophotometry to estimate genome copies and full/empty ratios adeno-associated virus particles.

The present disclosure discusses a method of separating a sample including oligonucleotides including coating a flow path of a chromatographic system; injecting the sample comprising oligonucleotides into the chromatographic system; flowing the sample through the chromatographic system; and separating the oligonucleotides. In some examples, the coating of the flow path is non-binding with respect to the analyte, such as oligonucleotides. Consequently, the analyte does not bind to the coating of the flow path. The non-binding coating eliminates the need for passivation, which can eliminate the formerly needed time to passivate as well. In addition, analyte can be recovered with a first injection in a system, such as chromatographic system.

A method to develop one or more morphometric classifiers to identify a mismatch repair deficiency (MMRD). The method provides a non-invasive method of characterizing MMRD that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.

The present technology relates to a method of separating a sample comprising oligonucleotides. The method includes injecting a polyphosphonic acid at a concentration of between about 0.01 M to about 1 M into the sample comprising oligonucleotides. The method also includes flowing the sample and polyphosphonic acid through a liquid chromatography column and separating the oligonucleotides.

Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides having hydrophobic portions (e.g., polyadenylated nucleic acids, such as mRNA) based upon the hydrophobic character of the molecules (e.g., polyA tail length). In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid having a hydrophobic portion (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by a mobile phase system that comprises an ion pairing agent selected from Tris, inorganic cations (including e.g., Na, Li, K, ammonium, etc.), biological buffers (e.g., MOPS, HEPES, PIPES, etc.), and other charged or hydrophilic moieties, and lacks conventional ion pairing agents (e.g., Triethylammonium acetate, TEAA). Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Methods and systems to perform genetically variant protein analysis and related marker genetic protein variations and databases, which in several embodiments allow performing a reliable genetic variation protein analysis in biological samples of different types and conditions taking into account the features of the biological sample where the analysis is performed.

The embodiments disclose a method including determining populations of Lactobacilli bacterial species associated with a predetermined health level for genital microbiome conditions to screen ointment preparations and ingredients for their impact on the well-being of said bacterial species, identifying the dominant Lactobacillus species in the predetermined health level for genital microbiome conditions, gathering culturing data and monitoring data of different optional cannabinoid or terpenoid compounds on genital Lactobacilli cultures, analyzing the culturing data and monitoring data to assay categorized impact data of the different optional cannabinoid or terpenoid compounds on the genital Lactobacilli cultures, and providing a diagnostic tool for screening the impact of a ointment preparations and ingredients on the genital community microbiomes for the design of safe, effective ointment preparations and ingredients for genital use.

The present invention relates to a method for detecting at least one oligonucleotide conjugate of interest in solution, wherein the oligonucleotide conjugate of interest is composed of a nucleic acid entity and of a nonpolar entity, wherein the nucleic acid entity is chemically linked to the nonpolar entity, and wherein the method comprises the steps of providing a liquid sample comprising the oligonucleotide conjugate of interest; separating the oligonucleotide conjugate of interest from the liquid sample by analytical means under conditions including the presence of at least one cyclodextrine in solution; and detecting the oligonucleotide conjugate of interest by means of qualitative or quantitative analysis.

Methods, kits, devices, and materials described herein provide blood-based diagnostic, prognostic, and treatment-monitoring biomarkers for IBS and IBD. These biomarkers can be used to distinguish IBS and/or IBD patients from healthy controls, for example, as well as to distinguish between IBS and IBD or other related disorders.